AI Terminal

MODULE: AI_ANALYST
Interactive Q&A, Risk Assessment, Summarization
MODULE: DATA_EXTRACT
Excel Export, XBRL Parsing, Table Digitization
MODULE: PEER_COMP
Sector Benchmarking, Sentiment Analysis
SYSTEM ACCESS LOCKED
Authenticate / Register Log In

Borregaard

Quarterly Report May 3, 2022

3562_rns_2022-05-03_3ad8d796-416d-458c-9781-6092dd752fd5.pdf

Quarterly Report

Open in Viewer

Opens in native device viewer

1 ST QUARTER 2022 INTERIM REPORT

CONTENTS

  • 1st quarter in brief
  • The Group
  • The business areas
  • BioSolutions
  • BioMaterials
  • Fine Chemicals
  • Foreign exchange and hedging
  • Cash flow and financial situation
  • Share information
  • Other matters and subsequent events
  • Outlook
  • The Group's interim condensed income statement
  • Interim earnings per share
  • The Group's interim condensed comprehensive income statement
  • The Group's interim condensed statement of financial position
  • Interim condensed changes in equity
  • The Group's interim condensed cash flow statement
  • Notes
  • Alternative performance measures

Q1 2022

1 S T QUARTER IN BRIEF

  • EBITDA¹ NOK 400 million (NOK 302 million)²
  • Improved result in all business areas
  • Increased sales prices and strong product mix in BioSolutions
  • Higher sales prices in BioMaterials
  • Increased deliveries and sales prices in Fine Chemicals
  • Higher energy, freight and raw material costs
  • Cash flow negatively affected by significant increase in net working capital

1 Alternative performance measure, see page 21 for definition.

2 Figures in parentheses are for the corresponding period in the previous year.

THE GROUP

1.1-31.3 1.1-31.12
Amounts in NOK million Note 2022 2021 2021
Operating revenues 2 1,615 1,419 5,805
EBITDA1 400 302 1,372
Operating profit 291 195 952
Profit/loss before taxes 2 277 176 873
Earnings per share (NOK) 2.18 1.47 6.95
Net interest-bearing debt1 11 1,535 1,675 1,417
Equity ratio1
(%)
61.7 56.9 60.1
Leverage ratio1 1.04 1.41 1.03
Return on capital employed1
(%)
17.4 12.4 16.1

OPERATING REVENUES EBITDA MARGIN1

EBITDA MARGIN1 EBITDA1

450

302

EBITDA1 NOK mill

450

400 391

Q1 Q2 Q3 Q4

2021 2022

416

263

EBITDA MARGIN1

OPERATING REVENUES

1,615

OPERATING REVENUES

1,615

NOK mill

Q1 Q2 Q3 Q4

Q1 Q2 Q3 Q4

2021 2022

1,511

2021 2022

1,511

NOK mill

0

500

700

900

1,100

1,300

1,500

1,700

0

500

700

900

1,100

1,300

1,500

1,700

EBITDA1 EARNINGS PER SHARE CUMULATIVE

FIRST QUARTER

Borregaard's operating revenues reached NOK 1,615 million (NOK 1,419 million)2 in the 1st quarter of 2022. EBITDA1 was NOK 400 million (NOK 302 million). The result increased in all business areas. The net currency impact on EBITDA1 was positive compared with the 1st quarter of 2021.

Higher sales prices and a strong product mix, partly offset by increased energy and freight costs, were the main reasons for the EBITDA1 improvement in BioSolutions. Higher sales prices more than compensated for lower deliveries and increased energy and raw material costs in BioMaterials. For Fine Chemicals, the EBITDA1 increase was due to higher deliveries and increased sales prices, partly offset by increased costs.

Operating profit reached NOK 291 million (NOK 195 million). Net financial items were NOK -14 million (NOK -19 million). Profit before tax was NOK 277 million (NOK 176 million). Tax expense of NOK -68 million (NOK -43 million), gave a tax rate of 25% (24%) in the quarter.

Earnings per share was NOK 2.18 (NOK 1.47).

Cash flow from operating activities was NOK -72 million (NOK 239 million). The cash flow was negatively affected by a significant increase in net working capital. This was mainly due to increased sales prices, affecting accounts receivable, and higher inventory values related to cost increases.

CASH FLOW FROM OPERATING ACTIVITIES

NOK mill

1 Alternative performance measure, see page 21 for definition.

2 Figures in parentheses are for the corresponding period in the previous year.

BUSINESS AREAS BIOSOLUTIONS

1.1-31.3 1.1-31.12
Amounts in NOK million 2022 2021 2021
Operating revenues 948 812 3,469
EBITDA1 261 205 942
EBITDA margin1
(%)
27.5 25.2 27.2

FIRST QUARTER

BioSolutions' operating revenues reached NOK 948 million (NOK 812 million). EBITDA1 increased to NOK 261 million (NOK 205 million).

Higher sales prices and a strong product mix were the main reasons for the EBITDA1 improvement, partly offset by substantial cost increases, primarily for energy and freight. In particular, the contribution from applications within agriculture, construction and oilfield chemicals increased. Net currency effects were positive.

The average price in sales currency was 23% higher than in the 1st quarter of 2021 due to price increases and a strong product mix. A tight market for synthetic vanillin and ethyl vanillin continued to have a positive impact.

The sales volume was 10% lower compared with the 1st quarter of 2021, mainly due to reduced raw material supply in the quarter, which primarily affected sales to low-value markets.

SALES VOLUME SALES VOLUME

Sales price and sales volume include lignin-based biopolymers and biovanillin.

  • 2 Figures in parentheses are for the corresponding period in the previous year.
  • 3 Average sales price is calculated using actual FX rates, excluding hedging impact.
  • 4 Metric tonne dry solid.

1 Alternative performance measure, see page 21 for definition.

BIOMATERIALS

1.1-31.3 1.1-31.12
2022 2021 2021
532 523 1,878
97 64 284
18.2 12.2 15.1

FIRST QUARTER

Operating revenues in BioMaterials were NOK 532 million (NOK 523 million) in the 1st quarter. EBITDA1 increased to NOK 97 million (NOK 64 million).

The effect of higher sales prices for speciality cellulose more than compensated for lower deliveries, increased energy spot prices and higher raw material costs. The net currency impact was positive.

The average price in sales currency increased by 19% due to strong demand and a tight specialty cellulose market.

The high sales volume in the 1st quarter of 2021 was due to a significant inventory reduction.

AVERAGE GROSS SALES PRICE5 AVERAGE GROSS SALES PRICE5

SALES VOLUME SALES VOLUME

Sales price and sales volume include speciality cellulose and cellulose fibrils.

5 Average sales price is calculated using actual FX rates, excluding hedging impact.

6 Metric tonne.

9,000

8,000

10,000

11,000

12,000

NOK per mt6

1 Alternative performance measure, see page 21 for definition.

FINE CHEMICALS

1.1-31.3 1.1-31.12
Amounts in NOK million 2022 2021 2021
Operating revenues 143 90 491
EBITDA1 42 33 146
EBITDA margin1
(%)
29.4 36.7 29.7

FIRST QUARTER

INGREDIENTS – SALES REVENUES

139 139

146

Q3

160

Q1 Q4

Q2

80

100 120 130

160 140

NOK million

40 60

20 0 Fine Chemicals' operating revenues were NOK 143 million (NOK 90 million). EBITDA1 increased to NOK 42 million (NOK 33 million).

EBITDA1 improved due to higher deliveries and increased sales prices, partly offset by increased costs. The net currency impact was positive.

The cost of the main raw material for fine chemical intermediates increased substantially, driven by energy prices. Bioethanol had higher deliveries and increased sales prices compared with the 1st quarter last year.

FINE CHEMICALS – SALES REVENUES

Sales revenues include pharma intermediates and bioethanol.

FOREIGN EXCHANGE AND HEDGING

Borregaard has a significant currency exposure which is hedged according to the company's hedging strategy. The impact of currency rate fluctuations will be delayed as a result of the currency hedging strategy. Compared with the 1st quarter of 2021, the net impact of foreign exchange on EBITDA1 , including hedging effects, was NOK 30 million. Hedging effects were NOK 10 million (NOK -15 million) in the quarter.

Assuming currency rates as of 2 May 2022 (USD 9.43 and EUR 9.92) and based on currency exposure forecasts, Borregaard expects a net impact of foreign exchange on EBITDA1 of approximately NOK 60 million in the 2nd quarter of 2022 and NOK 175 million for the full year of 2022.

CASH FLOW AND FINANCIAL SITUATION

FIRST QUARTER

1.1-31.3 1.1-31.12

Amounts in NOK million 2022 2021 2021 Operating revenues 143 90 491 EBITDA1 42 33 146

(%) 29.4 36.7 29.7

EBITDA margin1

Cash flow from operating activities in the 1st quarter was NOK -72 million (NOK 239 million). The cash flow was negatively affected by a significant increase in net working capital. This was mainly due to increased sales prices, affecting accounts receivable, and higher inventory values related to cost increases. The cash effect from an improved EBITDA1 was partly offset by higher tax payments compared with the 1st quarter of 2021.

Investments amounted to NOK 87 million (NOK 95 million). Expansion investments1 totalled NOK 16 million (NOK 36 million).

The Group has sold and repurchased treasury shares with net proceeds of NOK 23 million (NOK -27 million). Realised effect of hedging of net investments in subsidiaries was NOK 31 million (NOK 9 million).

On 31 March 2022, the Group had net interest-bearing debt1 totalling NOK 1,535 million (NOK 1,675 million), an increase of NOK 118 million from year-end 2021.

At the end of March, the Group was well capitalised with an equity ratio1 of 61.7% (56.9%) and a leverage ratio1 of 1.04 (1.41).

SHARE INFORMATION

In February, 200,000 share options at a strike price of NOK 228.75 were granted under the long-term incentive programme. The options will expire after five years, the vesting period is three years, and the options may be exercised during the last two years. For more details, see notification to Oslo Stock Exchange on 17 February 2022.

As part of the employee share programme, Borregaard sold a total of 162,810 shares to employees in February 2022. The price was NOK 152.50 per share after deduction of a 25% discount. For more details, see notifications to Oslo Stock Exchange on 7 and 14 February and 1 March 2022.

In the 1st quarter, 5,307 share options were exercised at a strike price of NOK 91.56 per share, 15,500 share options were exercised at a strike price of NOK 70.95 per share, and 5,000 share options were exercised at a strike price of NOK 75.30 per share.

In the 1st quarter, Borregaard repurchased a total of 21,620 treasury shares at an average price of NOK 188.43.

Total number of shares outstanding on 31 March 2022 was 100 million, including 247,865 treasury shares. Total number of shareholders was 8,022. Borregaard ASA's share price was NOK 174.40 at the end of the quarter (NOK 222.00 at the end of 2021).

OTHER MATTERS AND SUBSEQUENT EVENTS

New long-term sustainability-linked loan agreement

Borregaard has entered into a ten-year sustainabilitylinked loan agreement with the Nordic Investment Bank (NIB). The USD 50 million loan will contribute to financing Borregaard's investments to reduce CO2 emissions and water effluents. See notice to Oslo Stock Exchange as of 24 March 2022

Annual General Meeting

Borregaard ASA held its Annual General Meeting on 7 April 2022. The financial statements of Borregaard ASA and the Group, including the proposal to pay

an ordinary dividend of NOK 2.75 per share and an extraordinary dividend of NOK 2.25 per share, were approved. The dividend was paid out on 21 April 2022 with a total amount of NOK 499 million.

The Annual General Meeting re-elected Helge Aasen as the chair of the Board of Directors. Terje Andersen, Tove Andersen, Margrethe Hauge and John Arne Ulvan were re-elected as members of the Board. See notice to Oslo Stock Exchange as of 7 April 2022.

OUTLOOK

In 2022, the total sales volume in BioSolutions is expected to be slightly below the 2021 volume. The positive market development within several biopolymer applications is expected to continue, improving both product mix and average price in sales currency. The vanillin market is expected to remain strong, and the new biovanillin capacity will be phased gradually into the market. For the full year, cost increases, primarily driven by freight and energy costs, are expected to largely offset the effect of a positive market development.

In BioMaterials, the average price in sales currency for the full year is expected to be approximately 20% above the 2021 level, mainly driven by continued strong demand and a tight specialty cellulose market. Total sales volume for the full year is expected to be lower than in 2021, and aligned with the production volume. However, the volume of highly specialised grades is expected to be in line with 2021. The positive impact from price increases and an improved product mix will be partly offset by increased energy, raw

material and freight costs. Sales growth is expected to continue for cellulose fibrils.

The market conditions for biofuel in several EU countries are favourable with increased sales prices. Bioethanol sales will mainly be into these markets in 2022. An improved product mix for fine chemical intermediates is not expected to fully compensate for increased raw material costs.

Energy and raw material costs will increase in the 2nd quarter compared with the 1st quarter of 2022. Energy spot prices represent the largest uncertainty for the rest of the year.

Borregaard monitors potential consequences of the war in Ukraine closely. Sales to and sourcing from Russia, Belarus and Ukraine were limited prior to the war. Indirect consequences may occur as a result of potential impact on the global economy.

Sarpsborg, 2 May 2022 The Board of Directors of Borregaard ASA

THE GROUP'S INTERIM CONDENSED INCOME STATEMENT

1.1 - 31.3 1.1 - 31.12
Amounts in NOK million Note 2022 2021 2021
Operating revenues 2 1,615 1,419 5,805
Operating expenses -1,215 -1,117 -4,433
Depreciation property, plant and equipment -108 -106 -416
Amortisation intangible assets -1 -1 -4
Other income and expenses1 3 - - -
Operating profit 291 195 952
Financial items, net 4 -14 -19 -79
Profit before taxes 277 176 873
Income tax expense 5 -68 -43 -213
Profit for the period 209 133 660
Profit attributable to non-controlling interests -8 -13 -32
Profit attributable to owners of the parent 217 146 692
EBITDA1 400 302 1,372

INTERIM EARNINGS PER SHARE

1.1 - 31.3
Amounts in NOK 2022 2021 2021
Earnings per share (100 mill. shares) 6 2.18 1.47 6.95
Diluted earnings per share 6 2.17 1.46 6.94

THE GROUP'S INTERIM CONDENSED COMPREHENSIVE INCOME STATEMENT

1.1 - 31.3 1.1 - 31.12
Amounts in NOK million Note 2022 2021 2021
Profit for the period 209 133 660
Items not to be reclassified to P&L
Actuarial gains and losses (after tax) - - 55
Total - - 55
Items to be reclassified to P&L
Change in hedging-reserve after tax (cash flow) 8 124 136 86
Change in hedging-reserve after tax
(net investment in subsidiaries)
8 9 5 -9
Translation effects -4 -9 25
Total 129 132 102
The Group's comprehensive income 338 265 817
Comprehensive income non-controlling interests -9 -12 -28
Comprehensive income owners of the parent 347 277 845

THE GROUP´S INTERIM CONDENSED STATEMENT OF FINANCIAL POSITION

Amounts in NOK million Note 31.3.2022 31.12.2021
Intangible assets 13 86 89
Property, plant and equipment 13 4,180 4,191
Right-of-use assets 351 351
Other assets 9 393 339
Investments in joint venture/associate company 4 174 173
Non-current assets 5,184 5,143
Inventories 878 792
Receivables 9 1,416 1,107
Cash and cash deposits 11 103 124
Current assets 2,397 2,023
Total assets 7,581 7,166
Group equity 10 4,602 4,222
Non-controlling interests 75 84
Equity 4,677 4,306
Provisions and other liabilities 274 257
Interest-bearing liabilities 9, 11 1,418 1,320
Non-current liabilities 1,692 1,577
Interest-bearing liabilities 9, 11 223 224
Other current liabilities 9 989 1,059
Current liabilities 1,212 1,283
Equity and liabilites 7,581 7,166
Equity ratio1 61.7 % 60.1 %

INTERIM CONDENSED CHANGES IN EQUITY

1.1 - 31.3.2022 1.1 - 31.12.2021
Amounts in NOK million Note Controlling
interests
Non
controlling
interests
Total
equity
Controlling
interests
Non
controlling
interests
Total
equity
Equity 1 January 4,222 84 4,306 3,668 110 3,778
Profit/loss for the period 217 -8 209 692 -32 660
Items in Comprehensive Income 8 130 -1 129 153 4 157
The Group's Comprehensive income 8 347 -9 338 845 -28 817
Paid dividend - - - -249 - -249
Buy-back of treasury shares -4 - -4 -118 - -118
Exercise of share options 2 - 2 38 - 38
Reduced tax payable of exercised share options - - - - - -
Shares to employees 33 - 33 28 - 28
Option costs (share based payment) 2 - 2 10 - 10
Transactions with non-controlling interests - - - - 2 2
Equity at the end of the period 4,602 75 4,677 4,222 84 4,306

THE GROUP'S INTERIM CONDENSED CASH FLOW STATEMENT

1.1 - 31.3 1.1 - 31.12
Amounts in NOK million Note 2022 2021 2021
Profit before taxes 277 176 873
Amortisation, depreciation and impairment charges 109 107 420
Changes in net working capital, etc. -381 5 256
Dividend/share of profit from JV & associate company 4 - - 6
Taxes paid -77 -49 -124
Cash flow from operating activities -72 239 1,431
Investments property, plant and equipment
and intangible assets *
-87 -95 -556
Investment in associate company 4 - - -145
Other capital transactions 2 4 9
Cash flow from investing activities -85 -91 -692
Dividends - - -249
Proceeds from exercise of options/shares to employees 10 27 29 59
Buy-back of treasury shares 7 -4 -56 -118
Gain/(loss) on hedges for net investments in
subsidiaries
31 9 -14
Net paid to/from shareholders 54 -18 -322
Proceeds from interest-bearing liabilities 11 100 100 300
Repayment from interest-bearing liabilities 11 -14 -217 -814
Change in interest-bearing receivables/other liabilities 11 -2 -8 -1
Change in net interest-bearing liabilities 84 -125 -515
Cash flow from financing activities 138 -143 -837
Change in cash and cash equivalents -19 5 -98
Cash and cash equivalents at beginning of period 5 96 96
Change in cash and cash equivalents -19 5 -98
Currency effects cash and cash equivalents -2 -1 7
Cash and cash equivalents
at the close of the period
11 -16 100 5
*Investment by category
Replacement investments 71 59 398
Expansion investments1 16 36 303

NOTES

NOTE 01 Organisation and basis for preparation

GENERAL INFORMATION

Borregaard ASA is incorporated and domiciled in Norway. The address of its registered office is Hjalmar Wessels vei 6, Sarpsborg.

Basis for preparation

These unaudited Interim Condensed Consolidated Financial Statements are prepared in accordance with IAS 34 Interim Financial Reporting. Borregaard ASA is the parent company of the Borregaard Group presented in these Interim Condensed Consolidated Financial Statements.

The same accounting principles and methods of calculation have been applied as in the Consolidated Financial Statements for 2021 for the Borregaard Group.

Use of estimates

The same use of estimates has been applied as in the Consolidated Financial Statements for 2021.

NOTE 02 Segments

OPERATING REVENUES

1.1 - 31.3 1.1 - 31.12
Amounts in NOK million 2022 2021 2021
Borregaard 1,615 1,419 5,805
BioSolutions 948 812 3,469
BioMaterials 532 523 1,878
Fine Chemicals 143 90 491
Eliminations -8 -6 -33

There is limited intercompany sales between the different segments and eliminations consist essentially of allocations from the corporate headquarter.

cont. next page

cont. NOTE 02 Segments

EBITDA1

1.1 - 31.12
2022 2021 2021
400 302 1,372
261 205 942
97 64 284
42 33 146
1.1 - 31.3

Reconciliation against operating profit & profit before tax

EBITDA1 400 302 1,372
Depreciations and write downs -108 -106 -416
Amortisation intangible assets -1 -1 -4
Other income and expenses - - -
Operating profit 291 195 952
Financial items, net -14 -19 -79
Profit before taxes 277 176 873

SALES REVENUES

1.1 - 31.12
2022 2021 2021
1,591 1,394 5,715
929 793 3,392
522 513 1,840
141 88 485
-1 - -2
1.1 - 31.3

Operating revenues consist of sales revenues and other revenues such as commissions, revenues from waste received for incineration etc.

NOTE 03 Other income and expenses1

There are no Other income and expenses1 in the 1st quarter of 2022.

NOTE 04 Financial items

NET FINANCIAL ITEMS

1.1 - 31.3 1.1 - 31.12
Amounts in NOK million 2022 2021 2021
Net interest expenses -13 -16 -59
Currency gain/loss 1 1 -8
Share of profit/-loss from an associate -1 - -2
Other financial items, net -1 -4 -10
Net financial items -14 -19 -79

Borregaard holds 25% of the shares in Alginor ASA as of as of 31 March 2022.

1 Alternative performance measure, see page 21 for definition.

NOTE 05 Income tax expense

The tax rate of 24.5% (24.4%) for the first three months of 2022 is a compilation of the tax rates in the various countries in which Borregaard operates and has taxable income. The corporate income tax rate in Norway is 22%.

In addition to the compilation of the tax rates in the various countries in which Borregaard operates and has taxable income, the income tax rate for the Group is also impacted by the following: LignoTech Florida is a limited liability company (LLC) which is taxed on the owners' hand. Profit before tax is 100% consolidated

in the Borregaard Group, whereas the tax expense is calculated based on Borregaard's 55% ownership. Consequently, profit attributable to non-controlling interests for LignoTech Florida (45%) is calculated on profit before tax. Share of profit after tax from the joint venture, LignoTech South Africa, is accounted for as part of operating profit and profit before tax (due to IFRS 11). There are carry forward losses in the Group which will not be recognised as deferred tax assets, and hence increase the Group's tax rate.

NOTE 06 Earnings per share (EPS)

The share capital consists of 100 million shares. The company holds 247,865 treasury shares. As of 31 March 2022, there are 99,742,686 diluted shares (99,742,686 as of 31 December 2021). Earnings per diluted share were NOK 2.17 in the 1st quarter (NOK 1.46 in the 1st quarter of 2021).

NOTE 07 Stock options

During the 1st quarter of 2022, 5,307 share options were exercised at a strike price of NOK 91.56, 15,500 share options were exercised at a strike price of NOK 70.95 and 5,000 share options were exercised at a strike price of NOK 75.30 per share.

The Group Executive Management and other key employees hold a total of 1,410,467 stock options in five different share option programmes in Borregaard.

Stock options Issued 2017 Issued 2018 Issued 2019 Issued 2020 Issued 2021 Issued 2022
Number of stock options - 211,467 350,000 400,000 249,000 200,000
Strike price (NOK)* 91.56 70.95 75.30 99.60 180.70 228.75
Vesting period 3 years 3 years 3 years 3 years 3 years 3 years
Expiry date 17 February 2022 7 February 2023 6 February 2024 13 February 2025 16 February 2026 17 February 2027

* Strike prices as at 31 March 2022 have been adjusted for dividend paid since issuance of stock options.

NOTE 08 Statement of comprehensive income

The statement of comprehensive income shows changes in the value of hedging instruments, both cash flow

hedges and hedges of net investments in subsidiaries (hedging reserve). These figures are presented after tax.

31.3.2022 31.3.2021 31.12.2021
Amounts in NOK million Cash flow
hedges
Hedges of net
investments in
subsidiares
Cash flow
hedges
Hedges of net
investments in
subsidiares
Cash flow
hedges
Hedges of net
investments in
subsidiares
Tax effect year-to-date 74 -42 53 -41 39 -45
Hedging reserve after tax 261 -117 187 -112 137 -126

NOTE 09 Fair value hierarchy

For financial instruments that are recognised at fair value on a recurring basis, the Group determines whether transfers have occurred between levels in the hierarchy by re-assessing categorisation at the end of each reporting period.

The following measurement levels are used for determining the fair value of financial instruments:

  • Level 1 Quoted market prices in an active market (that are unadjusted) for identical assets or liabilities
  • Level 2 Valuation techniques (for which the lowest level input that is significant to the fair value measurement is directly or indirectly observable)

• Level 3 — Valuation techniques (for which the lowest level input that is significant to the fair value measurement is unobservable)

There were no transfers from one level to another in the measurement hierarchy from 2021 to the 1st quarter of 2022. Borregaard has no items defined as level 1. The bond is determined as measurement level 3. The fair value of the bond is deemed to equal its book value.

Set out below is a comparison of the carrying amount and the fair value of financial instruments as of 31 March 2022:

31.3.2022 31.12.2021
Amounts in NOK million Level Carrying amount Fair value Carrying amount Fair value
Non-current financial receivables 2 181 181 188 188
Non-current derivatives 2 195 195 136 136
Current derivatives 2 168 168 116 116
Total financial assets 544 544 440 440
FINANCIAL LIABILITIES
Non-current financial liabilities 2, 3 1,420 1,420 1,322 1,322
Non-current derivatives 2 10 10 30 30
Current financial liabilities 2 223 223 224 224
Current derivatives 2 23 23 32 32
Total financial liabilities 1,676 1,676 1,608 1,608

FINANCIAL ASSETS

cont. NOTE 09 Fair value hierarchy

FINANCIAL INSTRUMENTS MEASURED AT FAIR VALUE

Amounts in NOK million Level 1 Level 2 Level 3
Financial instruments 31.03.2022 -1,132 - -732 -400
Financial instruments 31.12.2021 -1,168 - -768 -400

The financial instruments are measured based on observable spot exchange rates, the yield curves of the respective currencies as well as the currency basis spreads between the respective currencies.

NOTE 10 Compilation of Equity

Amounts in NOK million 31.3.2022 31.12.2021
Share capital 100 100
Treasury shares - -
Share premium 1,346 1,346
Other paid-in capital 859 822
Translation effects 95 98
Hedging reserve (after tax) 144 11
Actuarial gains/Losses 41 41
Retained earnings 2,017 1,804
Group equity (controlling interests) 4,602 4,222

As of 31 March 2022, the company held 247,865 treasury shares at an average cost of NOK 203.32.

NOTE 11 Net interest-bearing debt1

The various elements of net interest-bearing debt are shown in the following table:

Amounts in NOK million 31.3.2022 31.12.2021
Non-current interest-bearing liabilities 1,418 1,320
Current interest-bearing liabilities including overdraft of cashpool 223 224
Non-current interest-bearing receivables (included in "Other Assets") -3 -3
Cash and cash deposits -103 -124
Net interest-bearing debt1 1,535 1,417
- of which impact of IFRS 16 Leases 373 371

NOTE 12 Related parties

The members of the Group Executive Management of Borregaard held a total of 719,361 stock options in the Company as of 31 March 2022.

NOTE 13 Assessments relating to impairment

No impairment indicators have been identified in the Borregaard Group's property, plant and equipment or intangible assets in the 1st quarter of 2022.

NOTE 14 Other matters and subsequent events

There have been no other events after the balance sheet date that would have had a material impact on the financial statements, or the assessments carried out.

ALTERNATIVE PERFORMANCE MEASURES

In the discussion of the reported operating results, financial position and cash flows, Borregaard refers to certain measures which are not defined by generally accepted accounting principles (GAAP) such as IFRS. Borregaard management makes regular use of these Alternative Performance Measures and is of the opinion that this information, along with comparable

GAAP measures, is useful to investors who wish to evaluate the company's operating performance, ability to repay debt and capability to pursue new business opportunities. Such Alternative Performance Measures should not be viewed in isolation or as an alternative to the equivalent GAAP measure.

MEASURE DESCRIPTION REASON FOR INCLUDING
EBITDA EBITDA is defined by Borregaard as operat
ing profit before depreciation, amortisation
and other income and expenses.
Shows performance regardless of capital
structure, tax situation and adjusted for
income and expenses related transactions
and events not considered by management to
be part of operating activities. Management
believes the measure enables an evaluation of
operating performance.
EBITDA MARGIN EBITDA margin is defined by Borregaard as
EBITDA divided by operating revenues.
Shows the operations' performance regardless
of capital structure and tax situation as a ratio
to operating revenue.
1.1-31.3 1.1-31.12
EBITDA 2022 2021 2021
Operating profit 291 195 952
Other income and expenses - - -
Amortisation intangible assets 1 1 4
Depreciation and impairment property, plant and equipment 108 106 416
EBITDA 400 302 1,372
1.1-31.3 1.1-31.12
EBITDA MARGIN 2022 2021 2021
EBITDA 400 302 1,372
Operating revenues 1,615 1,419 5,805
EBITDA margin (%) (EBITDA/operating revenues) 24.8 21.3 23.6
MEASURE DESCRIPTION REASON FOR INCLUDING
EQUITY RATIO Equity ratio is defined by Borregaard as
equity (including non-controlling interests)
divided by equity and liabilities.
describing the capital structure Equity ratio is an important measure in
EQUITY RATIO 31.03.2022 31.03.2021 31.12.2021
Total equity 4,677 4,027 4,306
Equity & liabilities 7,581 7,080 7,166
Equity ratio (%) (total equity/equity & liabilities) 61.7 56.9 60.1
MEASURE DESCRIPTION REASON FOR INCLUDING
EXPANSION INVESTMENTS Borregaard's investments are either
categorised as replacement or expansion.
Expansion investments is defined by Bor
regaard as investments made in order to
expand production capacity, produce new
products or to improve the performance of
existing products. Such investments include
business acquisitions, pilot plants, capital
ised research and development costs and
new distribution set-ups. In 2021, the major
expansion investments in Borregaard were
related to the investment in Alginor ASA and
the biovanillin capacity expansion.
Borregaard's strategic priorities are special
isation and diversification, increase value
added from the biorefinery, develop business
areas and to continue emphasis on ESG along
the entire value chain. To be able to deliver on
those priorities, expansion investments are
needed. As such, expansion investments are
important information for investors. One of
Borregaard's financial objectives is to have an
internal rate of return >15% pre-tax for expan
sion investments.
1.1-31.3 1.1-31.12
EXPANSION INVESTMENTS 2022 2021 2021
Investments property, plant and equipment and intangible assets 87 95 701
Replacement investments -71 -59 -398
Expansion investmests 16 36 303
MEASURE DESCRIPTION REASON FOR INCLUDING
OTHER INCOME AND EXPENSES Other income and expenses is defined by
Borregaard as non-recurring items or items
related to other periods or to a discontinued
business or activity. These items are not
viewed as reliable indicators of future earn
ings based on the business areas' normal
operations. These items will be included in
the Group's operating profit.
To be able to compare the EBITDA from year
to year, significant non-recurring items not
directly related to operating activities, are
included in Other income and expenses.
1.1-31.3
1.1-31.12
OTHER INCOME & EXPENSES 2022
2021
2021
Other income & expenses
-
- -
------------------------------ --- ---
MEASURE DESCRIPTION REASON FOR INCLUDING
NET INTEREST-BEARING DEBT Net interest-bearing debt is defined by Bor
regaard as interest-bearing liabilities minus
interest-bearing assets.
Net interest-bearing debt provides an indicator
of the net indebtedness and an indicator of the
overall strength of the statement of financial
position. Net interest-bearing debt is part of
Borregaard's financial covenants (leverage
ratio) and is important in understanding the
capital structure.
NET INTEREST-BEARING DEBT 31.03.2022 31.03.2021 31.12.2021
Total non-current interest-bearing liabilities 1,418 1,374 1,320
Total current interest-bearing liabilities including overdraft of cashpool 223 517 224

Non-current interest-bearing receivables (included in "Other assets") -3 -3 -3 Cash and cash equivalents -103 -213 -124 Net interest-bearing debt 1,535 1,675 1,417

MEASURE DESCRIPTION REASON FOR INCLUDING
LEVERAGE RATIO Leverage ratio is defined by Borregaard as
net interest bearing debt divided by last
twelve months' (LTM) EBITDA.
Leverage ratio is an indicator of the overall
strength of the statement of financial position.
Borregaard has a targeted leverage ratio
between 1.0 and 2.25 over time. Leverage ratio
is one of Borregaard's financial covenants on
long-term credit facilities.
LEVERAGE RATIO 31.03.2022 31.03.2021 31.12.2021
Net interest-bearing debt 1,535 1,675 1,417
EBITDA 1,470 1,192 1,372
Leverage ratio (net interest-bearing debt/EBITDA) 1.04 1.41 1.03
MEASURE DESCRIPTION REASON FOR INCLUDING
CAPITAL EMPLOYED Capital employed is defined by Borregaard
as the total of net working capital, intangible
assets, property, plant and equipment, right
of-use assets and investment in joint venture
and associate company minus net pension
liabilities.
Borregaard uses capital employed as basis for
calculating ROCE.
CAPITAL EMPLOYED (END OF YEAR) 31.03.2022 31.03.2021 31.12.2021
Capital employed (end of year) 6,421 5,884 6,043
MEASURE DESCRIPTION REASON FOR INCLUDING
RETURN ON CAPITAL EMPLOYED
(ROCE)
Return on capital employed (ROCE) is
defined by Borregaard as last twelve months'
(LTM) capital contribution (operating profit
before amortisation and other income
and expenses) divided by average capital
employed based on the ending balance of
the last five quarters.
ROCE is an important financial ratio to assess
Borregaard's profitability and capital efficien
cy. One of Borregaard's financial objectives
is to have ROCE >15% pre-tax over a business
cycle.
RETURN ON CAPITAL EMPLOYED (ROCE) 31.03.2022 31.03.2021 31.12.2021
Capital employed end of:
Q1, 2020 6,371
Q2, 2020 6,091
Q3, 2020 6,103
Q4, 2020 5,904 5,904
Q1, 2021 5,884 5,884 5,884
Q2, 2021 5,854 5,854
Q3, 2021 5,991 5,991
Q4, 2021 6,043 6,043
Q1, 2022 6,421
Average capital employed 6,038 6,071 5,935
EBITA
EBITDA 1,470 1,192 1,372
Depreciation and impairment property, plant and equipment -418 -440 -416
EBITA 1,052 752 956
RETURN ON CAPITAL EMPLOYED (ROCE)
EBITA 1,052 752 956
Average capital employed 6,038 6,071 5,935
Return on capital employed (ROCE) (%) (EBITA/average capital employed) 17.4 12.4 16.1

NOTES

NOTES

Q1 2022

FÆRD.no

Borregaard ASA P.O. Box 162, NO-1701 Sarpsborg, Norway Telephone: (+47) 69 11 80 00 Fax: (+47) 69 11 87 70 E-mail: [email protected] www.borregaard.com

Talk to a Data Expert

Have a question? We'll get back to you promptly.